Innkommet 12.12.2018 14:01
OSLO, Dec 12 (Reuters) - Norwegian drug maker Photocure
expects to boost the market share of its bladder cancer
treatment in the United States, resulting in solid revenue
growth, Chief Executive Daniel Schneider said on Wednesday.
“We have very strong revenue growth, with a year-to-date
growth of 45 percent in the U.S., and I don’t see that ending
any time soon. We have very low penetration in the U.S.,” the
recently appointed CEO told an investor conference in Oslo.
While most of Photocure’s growth will come from the U.S.
market in the short and medium term, the company could also
boost its sales in Norway, he added.
The company’s current U.S. revenue target is for $20
million-$25 million in 2020, up from $5.6 million in the first
nine months of 2018.
“We will update the market on the U.S. 2020 revenue outlook
at the latest when releasing full-year 2018 results,” Schneider
said.
Photocure’s share price traded 0.7 percent lower at 40.50
Norwegian crowns at 1300 GMT. Year-to-date it is up 48 percent.
(Reporting by Camilla Knudsen, editing by Terje Solsvik)
(([email protected]; +47 2331 6595; Reuters
Messaging: [email protected]))
Dette må da børsmeldes.???